FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	OVAL
OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5
	OMB Number: Estimated average burd

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Sawhney Amarpreet					2. Issuer Name and Ticker or Trading Symbol OCULAR THERAPEUTIX, INC [OCUL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Sawnne	<u>ey Amarp</u>	reet		٦						LOCOL		X Director	r	10% Ow	/ner	
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/02/2019						\dashv			Other (s below)	pecify	
C/O OCT	JLAR THE	RAPEUTIX, IN	C.	0	1/02/2	2019										
	SBY DRIVI			_ <u> </u>												
10 GROOD I DIGITE				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)												,	led by One Re	eporting Person		
BEDFOR	RD M	Α	01730										,	han One Report		
												Person		пап Опе Кероп	urig	
(City)	(5	tate)	(Zip)													
(Oity)	(0	iaic)	(2.17)													
		Ta	ble I - Non-D)erivati	ve Se	ecurities	s Ac	quired, D	isposed (of, or Be	neficiall	y Owned				
Date				Transaction ate Ionth/Day/	Execution Date,		Code (Instr.		ed (A) or str. 3, 4 and	5. Amour Securities Beneficia Owned Fo	Form ly (D) or	orm: Direct) or Indirect	7. Nature of ndirect Beneficial Ownership			
					•		Code	Amount	(A) o	r Price	Reported Transacti	ion(s)		Instr. 4)		
								Code	Amount	(D)	Price	(Instr. 3 a	nd 4)			
			Table II - De (e.					uired, Dis s, options	•	•	•	Owned				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A or Dispose of (D) (Instr. 3, 4 and 5)		e s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(3)		
Stock Option (Right to Buy)	\$4.1	01/02/2019		A		200,000		(1)	01/01/2029	Common Stock	200,000	\$0	200,000	D		
								<u> </u>			1					

Explanation of Responses:

 $1.\ Vests\ over\ four\ years,\ vesting\ 1/48\ monthly\ beginning\ on\ the\ one-month\ anniversary\ of\ the\ date\ of\ grant.$

/s/ Donald Notman, as

Attorney-in-Fact for Amarpreet 01/04/2019

<u>Sawhney</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.